BeiGene (NASDAQ:BGNE) Given New $236.00 Price Target at TD Cowen

BeiGene (NASDAQ:BGNE) had its price target hoisted by TD Cowen from $235.00 to $236.00 in a research note issued to investors on Wednesday, Benzinga reports. TD Cowen currently has a buy rating on the stock.

BGNE has been the topic of several other research reports. Guggenheim reduced their target price on shares of BeiGene from $350.00 to $345.00 and set a buy rating on the stock in a report on Tuesday, February 27th. JPMorgan Chase & Co. increased their price target on shares of BeiGene from $184.00 to $186.00 and gave the company an overweight rating in a research report on Tuesday, March 19th. Bank of America dropped their price target on shares of BeiGene from $179.30 to $164.30 and set a neutral rating for the company in a research report on Monday, April 8th. Finally, Sanford C. Bernstein dropped their price target on shares of BeiGene from $196.00 to $161.00 and set a market perform rating for the company in a research report on Wednesday, March 27th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $250.13.

BeiGene Price Performance

BGNE stock opened at $153.58 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.09 and a current ratio of 2.32. BeiGene has a 52 week low of $126.97 and a 52 week high of $266.67. The firm’s fifty day moving average is $154.84 and its 200 day moving average is $167.20. The firm has a market cap of $14.69 billion, a P/E ratio of -18.07 and a beta of 0.61.

BeiGene (NASDAQ:BGNE) last released its earnings results on Monday, February 26th. The company reported ($3.53) EPS for the quarter, beating the consensus estimate of ($3.61) by $0.08. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The company had revenue of $634.40 million for the quarter, compared to analyst estimates of $632.52 million. During the same quarter last year, the firm earned ($4.29) EPS. The firm’s quarterly revenue was up 66.9% compared to the same quarter last year. Research analysts predict that BeiGene will post -8.87 earnings per share for the current year.

Insider Transactions at BeiGene

In other news, CEO John Oyler sold 26,716 shares of the firm’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total value of $3,977,745.24. Following the completion of the sale, the chief executive officer now directly owns 12,084 shares of the company’s stock, valued at approximately $1,799,186.76. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CFO Julia Aijun Wang sold 397 shares of BeiGene stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $167.08, for a total transaction of $66,330.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Oyler sold 26,716 shares of BeiGene stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the transaction, the chief executive officer now directly owns 12,084 shares of the company’s stock, valued at $1,799,186.76. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,781 shares of company stock valued at $10,222,381. Company insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Simplicity Wealth LLC purchased a new position in BeiGene during the 1st quarter valued at about $885,000. Venturi Wealth Management LLC lifted its position in BeiGene by 87.0% during the 1st quarter. Venturi Wealth Management LLC now owns 2,845 shares of the company’s stock valued at $445,000 after acquiring an additional 1,324 shares during the period. LVW Advisors LLC lifted its position in BeiGene by 50.2% during the 1st quarter. LVW Advisors LLC now owns 1,957 shares of the company’s stock valued at $306,000 after acquiring an additional 654 shares during the period. Goldman Sachs Group Inc. lifted its position in BeiGene by 175.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock valued at $38,658,000 after acquiring an additional 136,458 shares during the period. Finally, Virtu Financial LLC lifted its position in BeiGene by 94.2% during the 4th quarter. Virtu Financial LLC now owns 5,319 shares of the company’s stock valued at $959,000 after acquiring an additional 2,580 shares during the period. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.